Collegium Pharmaceutical (NASDAQ: COLL)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Collegium Pharmaceutical Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Collegium Pharmaceutical Company Info
Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.
News & Analysis
It's not every day that a company graduates to a slot in a high-profile stock index.
These two companies aren't reinventing the wheel, but they still have the potential for tremendous growth.
These three health-related businesses are well positioned to provide market-beating gains.
This is the story of an emerging healthcare company on its way to capturing a billion-dollar market opportunity.
These are the two healthcare stocks that possess the best value for the greatest reward in May.
A company making abuse-deterrent opioids and that's barely listed in any nation-wide opioid litigation is becoming a rising star despite the prescription overdose crisis.
Investors aren't happy about the drugmaker's proposed senior convertible note offering.
The speciality pharmaceutical company purchased the full rights to an important drug product.
Valuation
Earnings Transcripts
COLL earnings call for the period ending September 30, 2021.
COLL earnings call for the period ending June 30, 2021.
COLL earnings call for the period ending March 31, 2021.
COLL earnings call for the period ending December 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.